Cullgen
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
12730 High Bluff Dr Ste 250, San Diego, ...Phone Number
(858) 284-0115Website
www.cullgen.comRevenue
$28.7 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Cullgen
Founded in 2018 and headquartered in San Diego, California, Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. They are developing a proprietary technology platform, ubiquitin-mediated, small molecule-induced target elimination technology, based on recent advances in the science of protein degradation.Explore more
Cullgen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cullgen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Cullgen is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Cullgen
Check if Cullgen has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Cullgen has new funding data
Earning: See what the market has to say on Cullgen recently announced quarterly report
Click to see if Cullgen had a recent Job posting/layoffs
Cullgen, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cullgen launches new products
Recommended Actions
Reach out to Masked Content who joined Cullgen as Masked Content
Find 3 more new buyers
Compare Similar Companies to Cullgen
Compare insights from companies similar to Cullgen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cullgen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cullgen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cullgen.
Cullgen financials insights
Gather financial insights about Cullgen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$16M
2021
Series B
$50M
2023
Series C
$40M
Cullgen Tech Stack
A closer look at the technologies used by Cullgen
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Open Position
Open Position
Cullgen News & Media
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
Gyre Therapeutics (GYRE) announced its agreement to acquire Cullgen, a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader antibody conjugate therapies, in an all-stock transaction valued at approximately $300M. Following the closure of the acquisition, the new combined entity will be a fully integrated biopharmaceutical company with U.S.- and China-based capabilities spanning from discovery to manufacturingGyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases, today announced its agreement to acquire Cullgen Inc. (Cullgen), a privately-held, clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DACullgen Announces Conference Participation During J.P. Morgan Healthcare Conference Week
- Updated corporate presentation posted to website -Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass., Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cullgen
Sign Up For FreeTo access detailed company insights
Founded in 2018 and headquartered in San Diego, California, Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. They are developing a proprietary technology platform, ubiquitin-mediated, small molecul... Read More
